BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35008270)

  • 1. Identification of Neoantigens in Two Murine Gastric Cancer Cell Lines Leading to the Neoantigen-Based Immunotherapy.
    Nagaoka K; Sun C; Kobayashi Y; Kanaseki T; Tokita S; Komatsu T; Maejima K; Futami J; Nomura S; Udaka K; Nakagawa H; Torigoe T; Kakimi K
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors.
    Sun C; Nagaoka K; Kobayashi Y; Maejima K; Nakagawa H; Nakajima J; Kakimi K
    Int J Cancer; 2023 Apr; 152(7):1463-1475. PubMed ID: 36451303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy.
    Nagaoka K; Shirai M; Taniguchi K; Hosoi A; Sun C; Kobayashi Y; Maejima K; Fujita M; Nakagawa H; Nomura S; Kakimi K
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Established gastric cancer cell lines transplantable into C57BL/6 mice show fibroblast growth factor receptor 4 promotion of tumor growth.
    Yamamoto M; Nomura S; Hosoi A; Nagaoka K; Iino T; Yasuda T; Saito T; Matsushita H; Uchida E; Seto Y; Goldenring JR; Kakimi K; Tatematsu M; Tsukamoto T
    Cancer Sci; 2018 May; 109(5):1480-1492. PubMed ID: 29532565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and Immune Profiling of Syngeneic Mouse Models Predict Response to Immune Checkpoint Inhibitors in Gastric Cancer.
    Lee D; Choi J; Oh HJ; Ham IH; Lee SH; Nomura S; Han SU; Hur H
    Cancer Res Treat; 2023 Jan; 55(1):167-178. PubMed ID: 35609622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
    Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology.
    Panni UY; Chen MY; Zhang F; Cullinan DR; Li L; James CA; Zhang X; Rogers S; Alarcon A; Baer JM; Zhang D; Gao F; Miller CA; Gong Q; Lim KH; DeNardo DG; Goedegebuure SP; Gillanders WE; Hawkins WG
    Cancer Immunol Immunother; 2023 Aug; 72(8):2813-2827. PubMed ID: 37179276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer.
    Guo Z; Yuan Y; Chen C; Lin J; Ma Q; Liu G; Gao Y; Huang Y; Chen L; Chen LZ; Huang YF; Wang H; Li B; Chen Y; Zhang X
    NPJ Precis Oncol; 2022 Jun; 6(1):34. PubMed ID: 35661819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.
    Łuksza M; Riaz N; Makarov V; Balachandran VP; Hellmann MD; Solovyov A; Rizvi NA; Merghoub T; Levine AJ; Chan TA; Wolchok JD; Greenbaum BD
    Nature; 2017 Nov; 551(7681):517-520. PubMed ID: 29132144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Neoantigens in Cancer Immunotherapy.
    Zhu Y; Liu J
    Front Oncol; 2021; 11():682325. PubMed ID: 34513673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy.
    Verdon DJ; Jenkins MR
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of neoantigen in immune checkpoint blockade therapy.
    Yi M; Qin S; Zhao W; Yu S; Chu Q; Wu K
    Exp Hematol Oncol; 2018; 7():28. PubMed ID: 30473928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
    Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
    Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1.
    Sun C; Nagaoka K; Kobayashi Y; Nakagawa H; Kakimi K; Nakajima J
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
    Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
    Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4.
    van den Bulk J; Verdegaal EME; Ruano D; Ijsselsteijn ME; Visser M; van der Breggen R; Duhen T; van der Ploeg M; de Vries NL; Oosting J; Peeters KCMJ; Weinberg AD; Farina-Sarasqueta A; van der Burg SH; de Miranda NFCC
    Genome Med; 2019 Dec; 11(1):87. PubMed ID: 31888734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
    Wirth TC; Kühnel F
    Front Immunol; 2017; 8():1848. PubMed ID: 29312332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.